faricimab


( Last Updated : November 16, 2022)
Generic Name:
faricimab
Project Status:
Complete
Therapeutic Area:
Macular degeneration, age-related
Manufacturer:
Hoffmann-La Roche Ltd.
Brand Name:
Vabysmo
Project Line:
Reimbursement Review
Project Number:
SR0719-000
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of Neovascular (wet) age-related macular degeneration (nAMD).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of Neovascular (wet) age-related macular degeneration (nAMD).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 23, 2021
Call for patient/clinician input closedFebruary 18, 2022
Clarification:

- Patient input submission received from Fighting Blindness Canada, The Canadian Council of the Blind, CNIB, Vision Loss Rehabilitation Canada

Submission receivedJanuary 31, 2022
Submission acceptedFebruary 14, 2022
Review initiatedFebruary 17, 2022
Draft CADTH review report(s) provided to sponsor for commentMay 04, 2022
Deadline for sponsors commentsMay 13, 2022
CADTH review report(s) and responses to comments provided to sponsorJune 10, 2022
Expert committee meeting (initial)June 22, 2022
Draft recommendation issued to sponsorJuly 05, 2022
Draft recommendation posted for stakeholder feedbackJuly 14, 2022
End of feedback periodJuly 28, 2022
Final recommendation issued to sponsor and drug plansAugust 12, 2022
Final recommendation postedAugust 30, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 26, 2022
CADTH review report(s) postedNovember 16, 2022